Project Grant R01AA031230

Award Date 8/20/24
Completion Date 5/31/29
Dollars Obligated $1.2M
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will provide $119,600 over a 3-year period from July 2024 to July 2027 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to conduct research on the mechanisms by which aging and alcohol consumption cooperatively contribute to the development of alcohol-associated liver disease (ALD). The project aims to identify how...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,547,718 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) from September 1, 2024 to May 31, 2029. The project will investigate the role of KDM5 demethylases in regulating cell-cell communication in the development and resolution of alcohol-associated liver disease. Specifically, the research aims to determine how KDM5B and KDM5C...
This $442,898 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support research to define the contributions of macrophage migration inhibitory factor (MIF) and its receptor CD74 in alcohol-associated liver disease (ALD). The research plan includes three specific aims: 1) characterizing the role of CD74 expression in hepatocytes and myeloid cells during and after ethanol feeding in mice, 2) resolving the...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $537,587 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The University of Texas Southwestern Medical Center to conduct research on the metabolic consequences of liver inflammation on alcohol consumption and alcohol-associated liver disease (ALD). The key objectives are to identify the mechanisms by which the transcription factor IRF3 suppresses the expression and secretion of the metabolic regulator...
This federal Project Grant award, valued at $523,477.00 and awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) on September 25, 2024, supports research to study alcohol-associated liver disease (ALD) and its interaction with the rs738409 variant in the PNPLA3 gene. The key products and services to be delivered under this grant include: Developing a human induced pluripotent stem cell (hiPSC)-derived in vitro liver culture...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support research to examine the role of non-parenchymal cells (NPCs) in driving the key features of Alcohol Associated Hepatitis (AAH) in a fully humanized mouse liver model. The $688,199 award to Yale University will fund research over a 5-year period from June 1, 2025 to February 28, 2030. The research aims to elucidate the NPC-derived...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
This federal Project Grant award of $380,863 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports research on the role of specific hepatic stellate cell subsets in the progression of alcohol-associated hepatitis (AH). The project aims to determine how the genes CYP1B1, PRRX1, and NR4A2 regulate the development and function of a novel FBLN2+ activated hepatic stellate cell (AHSC) subset in AH. Planned activities include...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under CFDA 93.273 - Alcohol Research Programs provides $374,598 to the University of Louisville to study the effects of alcohol consumption on chemical modifications to RNA and their potential contribution to the development and progression of alcohol-associated liver disease (ALD). The researchers will treat mice with alcohol, isolate different types of RNA from their livers, and use comprehensive 2D...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) received a $406,852 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The grant supports research to understand the molecular mechanisms by which alcohol decreases VMP1 (vacuole membrane protein 1) in pancreatic acinar cells, and how VMP1-mediated autophagy (ER-phagy) protects against alcohol-induced pancreatitis. The goal is to...

This Project Grant award of $1,158,934.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), will fund research to understand the mechanisms of mitochondrial dynamics, quality control, and mitochondrial DNA-mediated inflammation in alcohol-associated liver disease (ALD).

The key objectives are to investigate how chronically accumulated megamitochondria in the liver promote the release of mitochondrial DNA and activation of the cGAS-STING innate immune pathway, leading to alcohol-induced liver injury and tumorigenesis. The research aims to identify novel mechanisms regulating mitochondrial homeostasis that could inform new therapeutic approaches for ALD by targeting mitochondrial function. The award period runs from August 20, 2024 to May 31, 2029 and the work will be conducted by the University of Kansas Medical Center Research Institute, Inc.

Generated 8/5/25, 4:29 AM